

![]() |
|||||||||||||
|
| All | Since 2021 | |
| Citation | 7304 | 4079 |
| h-index | 28 | 23 |
| i10-index | 181 | 77 |
Submit Article
Search
News & Updation
GLOBAL REGULATORY PATHWAYS AND DESIGN CONTROL STANDARDS FOR HIGH-RISK CARDIOVASCULAR MEDICAL DEVICES: A COMPARATIVE REVIEW OF THE USA, EUROPEAN UNION AND INDIA
Karan Sharma, Keshav*
ABSTRACT High-risk cardiovascular medical devices, such as implantable pacemakers, implantable cardioverter-defibrillators (ICDs), coronary stents, prosthetic and transcatheter heart valves and ventricular assist devices, sustain or restore essential physiological functions, and their failure may lead to serious injury or death. These devices are therefore subject to the most stringent regulatory control in every major regulatory authority. Although regulatory systems share a common risk-based philosophy, they differ in classification terminology, pre-market pathways, conformity assessment, the explicitness of design-control requirements and the use of international standards. This review compares the regulatory frameworks of the United States of America (USA), the European Union (EU) and India with respect to risk classification, pre-market pathways, quality management systems (QMS), design controls, risk management, device-specific international standards (ISO, IEC and ASTM) and post-market obligations. The comparison shows that all three systems converge on a common technical foundation: risk-based classification, a mandatory QMS, integrated risk management, verification and validation, documentation and lifecycle surveillance. The principal differences lie in regulatory architecture and terminology. Gaps requiring further harmonization include the management of design changes, long-term clinical evidence, adaptive approaches for innovative devices, real-world standards (ISO, IEC and ASTM) and post-market obligations. The comparison shows that all three systems converge on a common technical foundation: risk-based classification, a mandatory QMS, integrated risk management, verification and validation, documentation and lifecycle surveillance. The principal differences lie in regulatory architecture and terminology. Gaps requiring further harmonization include the management of design changes, long-term clinical evidence, adaptive approaches for innovative devices, real-world Keywords: high-risk cardiovascular devices; regulatory pathways; design controls; ISO 13485; ISO 14971; FDA PMA; EU MDR; Medical Devices Rules 2017; regulatory convergence. [Download Article] [Download Certifiate] |
